Breast cancer: Biology, biomarkers, and treatments

Barzaman, Khadijeh; Karami, Jafar; Zarei, Zeinab; Hosseinzadeh, Aysooda; Kazemi, Mohammad Hossein; Moradi‐Kalbolandi, Shima; Safari, Elahe; Farahmand, Leila

doi:10.1016/j.intimp.2020.106535

Cited by 448 publications

(360 citation statements)

References 132 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…Clinical breast cancer (BC) cases exhibit striking inheritance, epigenetic, and phenotypic diversity, which complicates the difficulty of BC research [3]. Although there is improvement in the surgery, radiotherapy, chemotherapy, and endocrine therapy of BC, the prognosis of BC patients is still unsatisfactory [4]. In addition, targeted therapy has significantly improved the survival rate of BC patients over the past 30 years, providing a new thinking for BC therapy [5].…”

Section: Introductionmentioning

confidence: 99%

Hsa_circ_0001982 promotes the progression of breast cancer through miR-1287-5p/MUC19 axis under hypoxia

Qiu

Liu

2021

World J Surg Onc

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most commonly malignant tumor among women worldwide. Many studies have reported that circular RNAs (circRNAs) were participated in the regulation of multiple cancers development. However, the mechanism underlying hsa_circ_0001982 in breast cancer development is still unclear. Methods Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the levels of circ_0001982, microRNA-1287-5p (miR-1287-5p), and mucin 19 (MUC19) in BC tissues and cells under hypoxia. Moreover, glycolysis was evaluated by glucose consumption, lactic acid production, and hexokinase II (HK2) protein levels. The protein levels of cyclin D1, proliferating cell nuclear antigen (PCNA), and HK2 were determined by western blot assay. Cell proliferation, migration, and invasion were assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-h-tetrazolium bromide (MTT) and transwell assays, respectively. The relationship between miR-1287-5p and circ_0001982 or MUC19 was predicted using starbase v3.0 or Targetscan, and verified by dual-luciferase reporter assay and RNA binding protein immunoprecipitation (RIP) assay. The xenograft model in nude mice was established to examine the effect of circ_0001982 in vivo. Results The levels of circ_0001982 and MUC19 were upregulated, while miR-1287-5p was downregulated in BC tissues and cells under hypoxia. Knockdown of circ_0001982 hindered glycolysis, cell viability, migration, and invasion of BC cells under hypoxia. Mechanistic studies discovered that circ_0001982 could act as a sponge for miR-1287-5p to enhance MUC19 expression in BC cells. In addition, circ_0001982 silencing reduced xenograft tumor growth by regulating miR-1287-5p/MUC19 axis. Conclusion Circ_0001982 affected BC cells glycolysis, proliferation, migration, and invasion through miR-1287-5p/MUC19 axis under hypoxia.

show abstract

Section: Introductionmentioning

confidence: 99%

Hsa_circ_0001982 promotes the progression of breast cancer through miR-1287-5p/MUC19 axis under hypoxia

Qiu

Liu

2021

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…The remarkable ROS production in DHSF-BR16 cells could be related to the presence of many elongated mitochondria, sometimes very large, detected by electron microscope examination. Furthermore, since the overexpression of h-TERT and the oxidative stress increase cancer stem cell subpopulation (CSC) 31 , and CSC subpopulation is identified by CD133 32 and CD44 + /CD24 − phenotype, it is notable that DHSF-BR16 cells showed an up-regulation of CD133 and a CD44 + /CD24 −/low mixed phenotype, confirming the stemness profile.…”

Section: Discussionmentioning

confidence: 74%

Establishment and characterization of a new spontaneously immortalized ER−/PR−/HER2+ human breast cancer cell line, DHSF-BR16

Nobili

Mannini

Parenti

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Invasive ductal carcinoma (IDC) constitutes the most frequent malignant cancer endangering women’s health. In this study, a new spontaneously immortalized breast cancer cell line, DHSF-BR16 cells, was isolated from the primary IDC of a 74-years old female patient, treated with neoadjuvant chemotherapy and disease-free 5-years after adjuvant chemotherapy. Primary breast cancer tissue surgically removed was classified as ER−/PR−/HER2+, and the same phenotype was maintained by DHSF-BR16 cells. We examined DHSF-BR16 cell morphology and relevant biological and molecular markers, as well as their response to anticancer drugs commonly used for breast cancer treatment. MCF-7 cells were used for comparison purposes. The DHSF-BR16 cells showed the ability to form spheroids and migrate. Furthermore, DHSF-BR16 cells showed a mixed stemness phenotype (i.e. CD44+/CD24−/low), high levels of cytokeratin 7, moderate levels of cytokeratin 8 and 18, EpCAM and E-Cadh. Transcriptome analysis showed 2071 differentially expressed genes between DHSF-BR16 and MCF-7 cells (logFC > 2, p-adj < 0.01). Several genes were highly upregulated or downregulated in the new cell line (log2 scale fold change magnitude within − 9.6 to + 12.13). A spontaneous immortalization signature, mainly represented by extracellular exosomes-, plasma membrane- and endoplasmic reticulum membrane pathways (GO database) as well as by metabolic pathways (KEGG database) was observed in DHSF-BR16 cells. Also, these cells were more resistant to anthracyclines compared with MCF-7 cells. Overall, DHSF-BR16 cell line represents a relevant model useful to investigate cancer biology, to identify both novel prognostic and drug response predictive biomarkers as well as to assess new therapeutic strategies.

show abstract

“…1 Although the overall five-year survival rate for breast cancer patients exceeds 80%, metastasis to distant organs is still the main cause of breast cancer-related death. 2 Triple-negative breast cancer (TNBC) is an aggressive subtype that constitutes 12–18% of breast cancer patients. 3 , 4 TNBC patients lack the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), and therefore are ineligible for hormone or anti-HER2 therapy.…”

Section: Introductionmentioning

confidence: 99%

Key Role of MCUR1 in Malignant Progression of Breast Cancer

Gao

Peng

Lin

et al. 2021

OTT

View full text Add to dashboard Cite

Background: Mitochondrial calcium uniporter regulator 1 (MCUR1, also known as CCDC90A) is a protein-coding gene that plays a key role in mitochondrial calcium uptake. However, knowledge about its clinical significance in breast cancer is still limited. Methods: The expression profile of MCUR1 in various cancers was analyzed via the ONCOMINE and Tumor Immune Estimation Resource databases. The correlation between MCUR1 expression and the clinical features of breast cancer was investigated using UALCAN and MEXPRESS. Immunohistochemical analysis was applied to verify the expression of MCUR1 in breast cancer. The prognostic significance of MCUR1 in breast cancer was evaluated using Kaplan-Meier plotter and the PrognoScan database. Gene Set Enrichment Analysis (GSEA) was performed to explore the possible biological functions of MCUR1. In addition, the function of MCUR1 was examined by gene silencing in vitro. Western blotting was applied to detect the expression of proteins. Results: MCUR1 was overexpressed in breast cancer and significantly related to the clinical characteristics of breast cancer. Results from the public databases and IHC analysis indicated that MCUR1 expression was the highest in triple-negative breast cancer (TNBC). The high expression of MCUR1 was associated with poor overall survival, distant metastasis-free survival, and recurrence-free survival. GSEA showed that the hypoxia pathway, cellular reactive oxygen species (ROS) pathway, epithelial-mesenchymal transition pathway, and notch signaling pathway were differentially enriched in the high MCUR1 expression phenotype. In vitro experiments showed that MCUR1 knockdown in TNBC cell lines led to a decrease in cellular ROS and weakened cell migration and invasion abilities. Moreover, Western blotting showed that MCUR1 knockdown inhibited the epithelial-mesenchymal transition of TNBC cells via the ROS/Nrf2/Notch pathways. Conclusion:Our study suggests that MCUR1 plays a pivotal role in the malignant progression of breast cancer.

show abstract

Breast cancer: Biology, biomarkers, and treatments

Cited by 448 publications

References 132 publications

Hsa_circ_0001982 promotes the progression of breast cancer through miR-1287-5p/MUC19 axis under hypoxia

Hsa_circ_0001982 promotes the progression of breast cancer through miR-1287-5p/MUC19 axis under hypoxia

Establishment and characterization of a new spontaneously immortalized ER−/PR−/HER2+ human breast cancer cell line, DHSF-BR16

Key Role of MCUR1 in Malignant Progression of Breast Cancer

Contact Info

Product

Resources

About